Alzheimer’s disease (AD)

AXS-05 emerges as a potential first-in-class, non-antipsychotic treatment for Alzheimer’s agitation, positioning Axsome…

LEQEMBI’s subcutaneous formulation could simplify maintenance therapy for Alzheimer’s patients, offering a 15-second at-home…

Australia’s Alzheimer’s patients await potential treatment shift as TGA reviews Lilly’s donanemab following lecanemab rejection